ASBM Presents EU Survey Findings and Policy Updates at FDLI Annual Conference

April 23, 2014

ASBM Executive Director, Michael Reilly joined Kimberly Greco of Amgen and Christopher Mikson, MD of Jones Day for a biologics panel at the Food and Drug Law Institute’s (FDLI) 57th Annual Conference on April 23rd in Washington, DC. The panel was moderated by John Manthei, partner, Latham & Watkins, who also gave a brief overview […]

Read More

ASBM Attends WHO INN Stakeholders Open Session on Distinguishable Names

April 8, 2014

Geneva — ASBM was invited to share its perspectives before the World Health Organization’s 58th International Nonproprietary Names Consultation for Pharmaceutical Substances, Open Session for Stakeholders. At the meeting, ASBM Chairman Richard Dolinar, M.D., shared the results of a recent ASBM survey of European Physicians that concludes using the same INN for different biologic medicines […]

Read More

Multi-stakeholder Perspectives Video on Biosimilar Naming

April 2, 2014

ASBM member Global Healthy Living Foundation (GHLF), recently produced an educational video highlighting the need and importance of unique names for biosimilars. The video includes perspectives from Steve Marmaras of GHLF; Donna Cryer a prominent patient advocate who uses biologics; former FDA official Peter Pitts; as well as ASBM executive director Michael Reilly and RetireSafe […]

Read More

Indiana Governor Signs Biosimilars Legislation Ensuring Patient Safety

March 25, 2014

Arlington, VA – Today, the Alliance for Safe Biologic Medicines (ASBM) applauds Governor Mike Pence of Indiana in signing legislation to ensure the safe substitution of interchangeable biologic medicines, approved by the Food and Drug Administration (FDA). “We commend Indiana in taking the lead to make patient safety the priority as life-altering biologics become more […]

Read More

Pan-European survey calls for a shift in policy for biosimilars

March 18, 2014

Brussels — Today, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European physicians, that took place in Q3 of 2013, across five EU countries (France, Germany, Italy, Spain, and the UK), regarding their prescribing habits and knowledge of biosimilar medicines. Participants in the survey included specialists in the […]

Read More

Letter to the Editor: Urges safety first with biosimilars

March 17, 2014

VP of Advocacy and Public Policy for the Arthritis Foundation, Heartland Region writes in about Illinois Senate Bill.  Read more here.

Read More

ASBM Files Comments to the FTC

March 1, 2014

The Alliance for Safe Biologic Medicines submitted comments to the Federal Trade Commission in regards to the “Follow-On Biosimilars Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition” hearing held in February. Read comments here.

Read More

Opinion Article “As prescription drugs advance, doctors need all the details”

February 1, 2014

Opinion piece by Dr. Sol De Jesus in the Lebanon Daily News. Read here.

Read More

New IfPA publication on why doctors need to know when pharmacists substitute biologics.

January 17, 2014

“The Physician’s Perspective:  A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.

Read More

ASBM Presents New European Survey Findings on Biosimilars and the Importance of Nonproprietary Naming

November 22, 2013

Dublin, Ireland – The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians’ views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. […]

Read More